On July 20th, 2021 South Korea-based biotech company, Ubix Therapeutics (www.ubixtrx.com), reported the current status of their lead program, UBX-303, which utilizes Ubix’s platform technology, Degraducer (Press release, Ubix Therapeutics, JUL 20, 2021, View Source [SID1234635871]). UBX-303 is a Bruton’s tyrosine kinase (BTK) targeting molecule for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Ubix recently signed partnership agreements with global CRO and CDMO companies to initiate GLP toxicology studies as well as large-scale manufacturing of UBX-303 in preparation for submitting an Investigational New Drug (IND) application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chronic lymphocytic leukemia (CLL) patients face significant unmet needs, including the lack of treatment options for relapsed or refractory CLL, drug-induced resistance, and adverse events. Available BTK inhibitors can bind to off-target kinases, such as ITK and EGFR, causing side effects or can have limited long-term efficacy due to drug resistance, which most commonly occurs by the C481S mutation.

UBX-303 has been designed to demonstrate efficacy by degrading over-expressed BTK proteins and has a different modality than current BTK inhibitors. Its distinct mechanism of action, the decomposing and removal of BTK proteins in cells, is expected to bring about overall advantages, in particular demonstrating superior efficacy, overcoming resistance, and increasing selectivity for target proteins.

"UBX-303 showed excellent PK/PD profiles in the non-clinical studies conducted so far, and superior anti-cancer efficacy in the C481S mutant Xenograft mouse model as well as in the wild type. We expect UBX-303 to address unmet medical needs for B cell-related diseases, including CLL and DLBCL, and to expand its indications for immunological disorders." said BK Seo, CEO of Ubix Therapeutics.

About Degraducer
Degraducer is a technology that utilizes the ubiquitin-proteasome system (UPS), an intracellular degradation system. Degraducer is a bifunctional molecule where a "ligand", which binds to target protein, and a "binder", which binds to E3 ubiquitin ligase. In other words, Degraducer is a powerful inhibitor technology that enables target protein degradation and consequent therapeutic effects by placing a disease-related target protein nearby E3 ligase, which can then initiate the protein degradation system.

On July 20, 2021 ChromaDex Corp. (NASDAQ:CDXC) reported that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021 (Press release, ChromaDex, JUL 20, 2021, View Source [SID1234584964]). The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the second quarter results and provide a general business update on Tues., August 3, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

On July 20, 2021 Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, reported that it will report financial results for its first fiscal quarter ended June 30, 2021 on Tuesday, August 10, 2021 (Press release, Beyond Air, JUL 20, 2021, View Source [SID1234584981]). The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 20, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that it will host a key opinion leader webinar on Tuesday, July 27, 2021, at 8 am Eastern Time (Press release, Infinity Pharmaceuticals, JUL 20, 2021, View Source [SID1234584965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will provide updates on the MARIO-3 TNBC and MARIO-275 UC clinical studies, both of which add eganelisib to approved standard of care regimens. MARIO-3 is a Phase 2 triplet combination study evaluating the addition of eganelisib to the approved standard of care combination of Tecentriq and Abraxane in the front-line setting in TNBC. MARIO-275 is a randomized, controlled Phase 2 combination study evaluating the addition of eganelisib to the approved standard of care Opdivo monotherapy in the second line setting for immune-oncology naïve UC patients who have progressed on a platinum therapy.

The webinar will feature a presentation by Erika P. Hamilton, M.D. of Sarah Cannon Research Institute at Tennessee Oncolgy, of updated data from MARIO-3 in the context of the current standard of care. Dr. Hamilton presented initial MARIO-3 TNBC data at the 2020 San Antonio Breast Cancer Symposium in December 2020 and will be available to answer questions following the formal presentation.

Brian Schwartz, M.D., Consulting Chief Physician of Infinity, will present a status update on eganelisib in UC that builds upon the initial data from MARIO-275 Phase 2 study in second line patients with UC, which he presented at the 2021 ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium in February 2021 and will be available to answer questions following the formal presentation.

To register for the webinar, please click here.

Dr. Hamilton joined Sarah Cannon as investigator, drug development and women’s cancer in 2013. Her responsibilities include overseeing the breast cancer research program as well as caring for patients with breast and gynecologic cancers in the clinic. After receiving an undergraduate degree from Washington and Lee University in Virginia, Dr. Hamilton completed her medical degree and residency from University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke’s Annual House staff Fellow Teaching Award. Dr. Hamilton is board certified in internal medicine and oncology.

Dr. Brian Schwartz has more than a decade of experience as a drug development expert in pharmaceutical and biotechnology industries, spanning several therapeutic areas including oncology, dermatology, neurology and rare diseases. In senior leadership roles at ArQule, Ziopharm, Bayer and Leo Labs, Dr. Schwartz has accumulated a number of successful New Drug Applications (NDA), numerous Investigational New Drug (IND) applications, preclinical and clinical drug development programs. During his time in biotech, Dr. Schwartz acquired knowledge of investors relations, partnering and capital raising. Currently, Dr. Schwartz is an advisor for California Institute of Regenerative Medicine, numerous biotech companies and board member of LifeSci Acquisition Corp. Dr. Schwartz qualified as a medical doctor in South Africa followed by additional fellowship training in Canada.

On July 20, 2021 Pacira BioSciences, Inc. (NASDAQ:PCRX) reported that it will report its second quarter financial results before the open of the U.S. markets on Tuesday, August 3, 2021 (Press release, Pacira Pharmaceuticals, JUL 20, 2021, View Source [SID1234584982]). Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, dial 1-877-845-0779 and provide the passcode 9991311. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com.

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 9991311. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.